ANI Pharmaceuticals, Inc.

ANIP Healthcare Drug Manufacturers Specialty & Generic

ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024. In the quarter to June 2026, revenue grew 25.9%, EPS grew 194.6%, free cash flow fell 22.2% and total debt fell 1.78%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

72.08 0.20 −0.28%
Market cap
$1.7B
P/E
14.9×
Fwd P/E
14.5×
Dividend yield
—
F-score
7/9
Altman Z
2.30
Beneish M
−2.62
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
22.55 0.00 66.50 0.00 0.00 0.00 120.92 34.11 0.00 175.06
Piotroski F-Score
7 2 8 5 3 3 5 6 4 5
P/S ratio
1.79 1.74 2.11 2.06 2.69 1.67 3.54 2.61 4.49 5.45
Altman Z-Score
2.30 1.43 2.42 1.40 1.23 1.35 2.75 2.09 2.79 3.57
P/FCF ratio
10.49 18.39 10.25 0.00 0.00 0.00 40.38 9.36 0.00 0.00
Altman Z″-Score (non-manufacturers)
3.26 1.98 3.85 2.23 2.36 1.81 3.09 1.33 2.67 2.99
Beneish M-Score
(2.62) (2.41) (2.95) (2.36) (2.42) (2.47) (2.91) (3.06) (2.64) (1.36)
P/Operating CF
52.13 67.33 23.01 (147.97) (47.63) (60.86) 152.04 19.30 50.21 58.04
P/B ratio
2.93 2.65 2.38 2.08 1.74 1.78 3.43 2.67 4.54 4.13
Price to Tangible BV
0.00 0.00 5.27 19.24 48.86 96.27 25.34 0.00 0.00 0.00
EV/Sales
2.16 2.51 2.25 2.80 3.55 2.52 4.13 2.74 5.45 6.18
EV/EBITDA
9.41 18.81 10.25 36.29 102.90 18.35 14.00 8.01 17.14 18.73
EV/Operating CF
10.29 24.07 9.20 (28.34) 231.03 34.40 18.71 8.25 24.45 28.92
EV/FCF
12.63 26.53 10.89 (18.85) (43.44) (9.90) 47.21 9.85 (14.06) (6.53)
Quick Ratio
2.07 1.92 2.63 2.20 2.61 1.32 2.18 0.65 2.29 2.29
Current Ratio
2.71 2.72 3.57 3.46 3.68 2.17 3.04 0.92 3.35 3.22
Net Debt/EBITDA
1.59 5.77 0.60 9.57 25.08 6.21 2.02 0.40 3.03 2.20
Debt/Assets
42.84% 48.59% 31.59% 37.70% 37.24% 40.26% 40.66% 16.38% 48.89% 37.37%
Debt/Equity
1.14 1.46 0.62 0.85 0.80 0.95 0.87 0.36 1.15 0.71
Asset Turnover
0.65 0.56 0.58 0.41 0.35 0.45 0.47 0.48 0.48 0.42
Operating CF/Net income
2.40 (3.18) 6.93 0.63 (0.08) (0.68) 7.49 4.37 (36.63) 7.02
Capex/Depreciation
(0.38) (0.04) (0.31) (0.26) (0.44) (1.53) (0.62) (0.32) (3.87) (6.67)
Interest Coverage
5.54 0.03 1.74 (1.26) (3.34) (1.69) 1.26 2.40 2.35 1.77
ROE
16.34% (4.82%) 4.60% (15.29%) (16.16%) (11.04%) 2.97% 8.25% (0.62%) 2.37%
ROA
5.66% (1.84%) 2.06% (6.47%) (6.94%) (4.91%) 1.37% 3.64% (0.29%) 1.29%
ROIC
8.05% 0.04% 5.62% (3.86%) (4.56%) (2.68%) 3.04% 9.83% 5.13% 4.77%
Return on Tangible Assets
14.36% (5.15%) 4.09% (17.19%) (14.92%) (16.95%) 3.66% 60.35% (0.95%) 4.77%
Average Days of Receivables
116.14 131.73 121.52 190.86 217.05 167.72 127.46 117.41 121.34 130.24
Research and Development Expense of Revenue
5.85% 7.26% 7.04% 7.05% 5.26% 7.68% 9.59% 7.63% 5.13% 2.26%
Selling, General and Administrative Expense of Revenue
35.97% 40.63% 33.22% 39.21% 39.00% 31.17% 27.04% 21.86% 17.86% 21.64%
Intangible Assets out of Total Assets
0.38 0.47 0.26 0.37 0.42 0.42 0.40 0.48 0.56 0.55
Share Based Compensation of Revenue
4.29% 4.78% 4.24% 4.61% 4.85% 6.21% 4.46% 3.36% 3.44% 4.72%
Graham Net Nets
(0.09) (0.31) 0.07 (0.12) (0.16) (0.27) (0.08) (0.15) (0.13) (0.07)
Graham Number
46.08 0.00 21.57 0.00 0.00 0.00 14.36 22.40 0.00 10.80
Earnings Yield
4.43% (2.03%) 1.50% (7.59%) (7.06%) (6.47%) 0.83% 2.93% (0.13%) 0.57%
Free Cash Flow Yield
9.53% 5.44% 9.76% (7.20%) (3.04%) (15.27%) 2.48% 10.68% (8.64%) (17.34%)
Revenue per Share
44.05 31.80 27.04 19.46 17.16 17.43 17.44 17.26 15.32 11.24
Operating CF per Share
9.24 3.31 6.61 (1.92) 0.26 1.28 3.85 5.74 3.41 2.40
Capex per Share
(1.71) (0.18) (1.03) (0.97) (1.67) (5.71) (2.33) (0.93) (9.35) (13.02)
Free Cash Flow per Share
7.53 3.14 5.58 (2.88) (1.40) (4.43) 1.53 4.81 (5.94) (10.62)
Cash per Share
14.70 7.83 12.28 3.27 7.96 0.66 5.26 3.68 2.70 2.39
Shareholders Equity per Share
26.96 22.18 25.42 20.82 28.48 16.36 17.97 16.89 15.13 14.82
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
26.96 22.18 25.42 20.82 28.48 16.36 17.97 16.89 15.13 14.82
Free Cash Flow
150.90 60.58 100.45 (46.91) (17.67) (53.05) 18.08 56.16 (68.57) (121.59)
Working Capital
475.01 334.00 374.34 244.82 234.24 91.76 126.02 (12.67) 92.38 71.06
Capital Expenditures
(34.32) (3.44) (18.51) (15.70) (20.99) (68.32) (27.55) (10.91) (107.99) (149.06)
Net Current Asset Value
(146.54) (327.48) 72.99 (77.29) (91.08) (95.17) (56.30) (80.46) (105.78) (50.21)
EV/EBIT
17.15 2,638.34 23.29 0.00 0.00 0.00 52.21 15.65 34.03 39.57
Capex to Sales
0.04 0.01 0.04 0.05 0.10 0.33 0.13 0.05 0.61 1.16
Price to Operating Income
14.25 1,828.59 21.92 0.00 0.00 0.00 44.66 14.87 28.01 34.92
Other line items
Depreciation/Fixed assets
1.46 1.43 1.34 1.38 0.90 1.08 1.10 0.89 1.37 2.03
Cash ROIC
10.39% 5.03% 10.42% (6.92%) (2.37%) (13.63%) 3.92% 18.07% (16.83%) (38.28%)
Accounts Receivable Turnover
3.51 3.20 2.97 2.15 1.93 2.48 3.02 3.26 3.38 3.79
Accounts Payable Turnover
6.31 6.08 5.50 5.31 5.88 6.74 5.38 11.67 22.52 17.88
Inventory Turnover
2.44 2.02 1.68 1.48 1.41 1.60 1.42 1.87 2.47 2.47
Average Days of Payables
66.93 66.60 73.76 77.07 83.32 47.16 84.42 44.41 16.76 25.36
Days of Inventory on Hand
153.00 199.53 223.60 277.08 296.37 254.63 278.36 202.45 174.24 195.92
Average Receivables
251.40 191.90 163.76 146.98 112.16 83.96 68.49 61.82 52.34 33.91
Average Payables
54.12 41.17 32.99 26.14 17.11 12.93 11.75 6.26 3.51 2.73
Average Inventory
139.92 123.99 108.28 93.52 71.25 54.48 44.33 39.12 31.96 19.79
Average Assets
1,362.42 1,094.45 832.25 765.84 616.39 458.99 443.70 421.37 367.50 304.06
Average Common Equity
472.20 418.21 373.22 323.79 264.80 204.25 205.03 186.01 172.20 164.87

Fold the line items

Columns are period end dates